Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Betekom – page 141

1 978 clinical trials in Betekom, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Betekom at a glance
1 978
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 978 trials in Betekom

Open in trial search

IgA nephropathy

Not recruiting

Study on Ravulizumab for Adults with Immunoglobulin A Nephropathy (IgAN) to Preserve Kidney Function

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Study of ibrutinib and venetoclax combination therapy for patients with relapsed or refractory chronic lymphocytic leukemia who have adequate kidney function

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study of inavolisib, palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:F. Hoffmann-La Roche AG

Study of Lurbinectedin Alone or with Irinotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Irinotecan
  • Sponsor:Pharma Mar S.A.

Short-bowel syndrome

Not recruiting

Long-term safety study of apraglutide (weekly injections) in patients with Short Bowel Syndrome

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Apraglutide
  • Sponsor:VectivBio AG

Multiple sclerosis

Not recruiting

Study on Long-Term Safety and Efficacy of Ocrelizumab for Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Plasma cell myeloma+13

Not recruiting

Study on Atezolizumab and Drug Combinations for Advanced Malignancies in Patients from Previous Atezolizumab Trials

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:F. Hoffmann-La Roche AG

Dry eye+1

Not recruiting

Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ianalumab
  • Sponsor:Novartis Pharma AG

Asthma

Not recruiting

Study on the Long-term Effects of Dupilumab in Preventing Lung Function Decline in Adults with Uncontrolled Moderate to Severe Asthma

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on the Effectiveness and Safety of Avalglucosidase Alfa for Babies with Infantile-Onset Pompe Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Avalglucosidase Alfa
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on Pembrolizumab for Patients with High-Risk Stage III Melanoma After Surgery

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study of DYNE-251 safety and effectiveness in patients with Duchenne muscular dystrophy who are candidates for exon 51 skipping treatment

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Fragment Antibody Targeting Human Tfr1 Conjugated To Phosphorodiamidate Morpholino Oligomer
  • Sponsor:Dyne Therapeutics Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Betekom

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on optimizing treatment strategies for patients with functional dyspepsia and related gastrointestinal conditions. This study explores effective methods for reducing long-term dependency on proton pump inhibitors (PPIs).

  • Medication De-prescribing Strategies
  • Gastrointestinal Health Management
  • Alternative Treatment Approaches

The research evaluates various therapeutic approaches, including on-demand medication use and alternative treatments, aiming to improve patient care in primary healthcare settings.

02 Primary Care Innovation

A groundbreaking study examining the effectiveness of different approaches to managing chronic acid reflux and heartburn symptoms. This research aims to establish more patient-centered treatment protocols.

  • Patient-Centered Care
  • Long-term Medication Management
  • Treatment Optimization

The trial explores innovative strategies to help patients safely reduce their dependence on long-term acid suppression therapy while maintaining symptom control.

03 Therapeutic Alternatives

Investigation into the comparative effectiveness of different treatment strategies for digestive disorders, including traditional medication tapering and alternative therapeutic approaches.

  • Medication Alternatives
  • Symptom Management
  • Quality of Life Impact

This research evaluates various therapeutic options, including alginate-based treatments, to provide evidence-based alternatives for long-term acid suppression therapy.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.